New research suggests troubling phenomenon brewing in Antarctic waters — here's what we should prepare for
The Antarctic Circumpolar Current may be moving 20% slower by 2050, according to research described in The Conversation.
Surrounding Antarctica in a ring, the Antarctic Circumpolar Current is the strongest ocean current in the world. However, its remote location has historically made it challenging to study, so it's not as well-understood as other currents of its caliber, as the researchers noted.
However, modern technology has allowed researchers to delve into this subject further. Australia-based researchers Taimoor Sohail and Bishakhdatta Gayen, along with their colleague Andreas Klocker, used a supercomputer and climate simulator to predict future patterns of currents.
"The model captures features others often miss, such as eddies," Sohail and Gayen explain in the Conversation. "So it's a far more accurate way to assess how the current's strength and behaviour will change. … It picks up the intricate interactions between ice melting and ocean circulation."
The results weren't encouraging. The projection predicted that fresh water from newly melted Antarctic ice would flow northward and penetrate the deep sea, ultimately slowing the current.
As the researchers detailed, the Antarctic Circumpolar Current keeps things in balance. Its chilly temperatures protect the Antarctic from warm water that could melt its shores and disturb its ecosystem. It links the Pacific, Atlantic, and Indian currents, and plays a crucial role in regulating the current climate.
If the current slows down, a lot could change. A weaker current would harm fisheries that are important to coastal communities. Pesky invasive species could also worm their way into Antarctic ecosystems, pushing native species out and disrupting the ecosystem's already delicate balance.
Such increased competition for resources can lead to the extinction of marine species. Polar ice melting can also trigger domino effects across the rest of the globe, even contributing to droughts and heat waves.
Yes, this prediction is bad. No, it's not hopeless. If this comes to pass, it won't happen until 2050. There's still time to limit the melting and keep the Antarctic Circumpolar Current intact.
Many organizations are dedicated to combating critical climate issues like this one. For instance, one Dutch startup, Arctic Reflections, is looking to restore Arctic sea ice by pumping cool water onto the ocean's surface.
Should we be harnessing the ocean to power our homes?
Absolutely
Leave it be
It depends
I'm not sure
Click your choice to see results and speak your mind.
If you want to do your part to slow the planet's warming, you could install solar panels, upgrade to an induction stove, or donate to climate causes, among many other possibilities designed around the primary goal of helping yourself while helping the planet that are covered in the TCD Guide.
However, it's important to remember that big issues like this can't be fully addressed without policy changes. Sohail and Gayen explained in the Conversation that "proactive and coordinated international actions" are the key to the planet's healthy future.
Join our free newsletter for good news and useful tips, and don't miss this cool list of easy ways to help yourself while helping the planet.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Private Japanese lunar lander heads toward a touchdown in the moon's far north
A private lunar lander from Japan is closing in on the moon, aiming for a touchdown in the unexplored far north with a mini rover. The moon landing attempt by Tokyo-based company ispace on Friday Japan time is the latest entry in the rapidly expanding commercial lunar rush. The encore comes two years after the company's first moonshot ended in a crash landing, giving rise to the name Resilience for its successor lander. Resilience holds a rover with a shovel to gather lunar dirt as well as a Swedish artist's toy-size red house that will be lowered onto the moon's dusty surface. Long the province of governments, the moon became a target of private outfits in 2019, with more flops than wins along the way. Launched in January from Florida on a long, roundabout journey, Resilience entered lunar orbit last month. It shared a SpaceX ride with Firefly Aerospace's Blue Ghost, which reached the moon faster and became the first private entity to successfully land there in March. Another U.S. company, Intuitive Machines, arrived at the moon a few days after Firefly. But the tall, spindly lander face-planted in a crater near the moon's south pole and was declared dead within hours. Resilience is targeting the top of the moon, a less forbidding place than the shadowy bottom. The ispace team chose a flat area with few boulders in Mare Frigoris or Sea of Cold, a long and narrow region full of craters and ancient lava flows that stretches across the near side's northern tier. Once settled with power and communication flowing, the 7.5-foot (2.3-meter) Resilience will lower the piggybacking rover onto the lunar surface. Made of carbon fiber-reinforced plastic with four wheels, ispace's European-built rover — named Tenacious — sports a high-definition camera to scout out the area and a shovel to scoop up some lunar dirt for NASA. The rover, weighing just 11 pounds (5 kilograms), will stick close to the lander, going in circles at a speed of less than one inch (a couple centimeters) per second. Besides science and tech experiments, there's an artistic touch. The rover holds a tiny, Swedish-style red cottage with white trim and a green door, dubbed the Moonhouse by creator Mikael Genberg, for placement on the lunar surface. Takeshi Hakamada, CEO and founder of ispace, considers the latest moonshot 'merely a steppingstone,' with its next, much bigger lander launching by 2027 with NASA involvement, and even more to follow. 'We're not trying to corner the market. We're trying to build the market,' Jeremy Fix, chief engineer for ispace's U.S. subsidiary, said at a conference last month. 'It's a huge market, a huge potential." Fix noted that ispace, like other businesses, does not have 'infinite funds' and cannot afford repeated failures. While not divulging the cost of the current mission, company officials said it's less than the first one which exceeded $100 million. Two other U.S. companies are aiming for moon landings by year's end: Jeff Bezos' Blue Origin and Astrobotic Technology. Astrobotic's first lunar lander missed the moon altogether in 2024 and came crashing back through Earth's atmosphere. For decades, governments competed to get to the moon. Only five countries have pulled off successful robotic lunar landings: Russia, the U.S., China, India and Japan. Of those, only the U.S. has landed people on the moon: 12 NASA astronauts from 1969 through 1972. NASA expects to send four astronauts around the moon next year. That would be followed a year or more later by the first lunar landing by a crew in more than a half-century, with SpaceX's Starship providing the lift from lunar orbit all the way down to the surface. China also has moon landing plans for its own astronauts by 2030. ___ The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Science and Educational Media Group and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.
3 hours ago
Private Japanese lunar lander heads toward a touchdown in the moon's far north
A private lunar lander from Japan is closing in on the moon, aiming for a touchdown in the unexplored far north with a mini rover. The moon landing attempt by Tokyo-based company ispace on Friday Japan time is the latest entry in the rapidly expanding commercial lunar rush. The encore comes two years after the company's first moonshot ended in a crash landing, giving rise to the name Resilience for its successor lander. Resilience holds a rover with a shovel to gather lunar dirt as well as a Swedish artist's toy-size red house that will be lowered onto the moon's dusty surface. Long the province of governments, the moon became a target of private outfits in 2019, with more flops than wins along the way. Launched in January from Florida on a long, roundabout journey, Resilience entered lunar orbit last month. It shared a SpaceX ride with Firefly Aerospace's Blue Ghost, which reached the moon faster and became the first private entity to successfully land there in March. Another U.S. company, Intuitive Machines, arrived at the moon a few days after Firefly. But the tall, spindly lander face-planted in a crater near the moon's south pole and was declared dead within hours. Resilience is targeting the top of the moon, a less forbidding place than the shadowy bottom. The ispace team chose a flat area with few boulders in Mare Frigoris or Sea of Cold, a long and narrow region full of craters and ancient lava flows that stretches across the near side's northern tier. Once settled with power and communication flowing, the 7.5-foot (2.3-meter) Resilience will lower the piggybacking rover onto the lunar surface. Made of carbon fiber-reinforced plastic with four wheels, ispace's European-built rover — named Tenacious — sports a high-definition camera to scout out the area and a shovel to scoop up some lunar dirt for NASA. The rover, weighing just 11 pounds (5 kilograms), will stick close to the lander, going in circles at a speed of less than one inch (a couple centimeters) per second. Besides science and tech experiments, there's an artistic touch. The rover holds a tiny, Swedish-style red cottage with white trim and a green door, dubbed the Moonhouse by creator Mikael Genberg, for placement on the lunar surface. Takeshi Hakamada, CEO and founder of ispace, considers the latest moonshot 'merely a steppingstone,' with its next, much bigger lander launching by 2027 with NASA involvement, and even more to follow. 'We're not trying to corner the market. We're trying to build the market,' Jeremy Fix, chief engineer for ispace's U.S. subsidiary, said at a conference last month. 'It's a huge market, a huge potential." Fix noted that ispace, like other businesses, does not have 'infinite funds' and cannot afford repeated failures. While not divulging the cost of the current mission, company officials said it's less than the first one which exceeded $100 million. Two other U.S. companies are aiming for moon landings by year's end: Jeff Bezos' Blue Origin and Astrobotic Technology. Astrobotic's first lunar lander missed the moon altogether in 2024 and came crashing back through Earth's atmosphere. For decades, governments competed to get to the moon. Only five countries have pulled off successful robotic lunar landings: Russia, the U.S., China, India and Japan. Of those, only the U.S. has landed people on the moon: 12 NASA astronauts from 1969 through 1972. NASA expects to send four astronauts around the moon next year. That would be followed a year or more later by the first lunar landing by a crew in more than a half-century, with SpaceX's Starship providing the lift from lunar orbit all the way down to the surface. China also has moon landing plans for its own astronauts by 2030. ___ The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Science and Educational Media Group and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.
Yahoo
4 hours ago
- Yahoo
Juvenescence acquires AI drug discovery company Ro5 to boost R&D capabilities and drive pipeline of medicines to extend healthy lifespan
Ro5 Inc. acquisition enhances artificial intelligence/machine learning drug discovery capabilities Strategic addition strengthens Juvenescence's AI-enabled therapeutics pipeline and supports partnership with M42 (Mubadala) Acquisition follows $76m Series B-1 financing first-close led by M42 in May 2025 Ramsey, Isle of Man, 5 June 2025: Juvenescence Limited, a clinical stage AI-enabled biotech company, is pleased to announce the acquisition of Ro5 Inc., a proprietary AI drug discovery company. This acquisition enhances Juvenescence's artificial intelligence/machine learning drug discovery capabilities and forms a central component of its strategic partnership with Abu Dhabi-based global healthcare company M42, announced in April 2025. Ro5's platform leverages a proprietary Biomedical Knowledge Graph, comprising over 85 million nodes and approximately 400 million relationships, to uncover novel associations in biological processes and enable a robust evaluation of drug targets based on biological, therapeutic, and market potential. The Company's AI Chemistry Platform incorporates state-of-the art machine learning model and cheminformatics tools, facilitating rapid and efficient discovery and design of novel compounds from hit identification through to lead optimisation. The acquisition of Ro5 follows Juvenescence's recent announcement of a $76 million first-close of its Series B-1 financing round led by cornerstone investor M42, with follow-on investments from existing investors. The second close of the Series B-1 is anticipated in the third quarter of 2025. Proceeds will support clinical milestones and AI-driven development across Juvenescence's portfolio of therapeutics targeting age-related diseases. The integration of Ro5's AI drug discovery platform and expert team into Juvenescence will accelerate the identification and development of AI-enabled therapeutics, reinforcing the company's growing pipeline in cognition, cardio-metabolism, immunity, and cellular Richard Marshall CBE, CEO of Juvenescence, said: 'We are delighted to welcome the Ro5 team and the Company's capabilities into Juvenescence. The addition of Ro5's AI platform significantly enhances our drug discovery capabilities, accelerating our efforts to identify and advance effective therapeutics to extend healthspan. This acquisition is also a critical part of our wider strategy with M42 to deliver a pipeline of transformative therapies and establish a world-class life sciences hub in Abu Dhabi. Together, we remain committed to improving the lives of millions of patients.' Charles Dazler Knuff, CEO of Ro5, added: 'The Ro5 team are thrilled to be joining the world class drug development team at Juvenescence. Embedding our AI-driven drug discovery capabilities into Juvenescence's operations will accelerate their ability to advance next-generation therapeutics. Together with our partners at M42 we are also laying the foundations for a pioneering life sciences ecosystem in Abu Dhabi that leverages AI innovation to transform patient care and global health outcomes.' About Juvenescence Juvenescence is a clinical-stage AI-enabled biotech company developing novel medicines to extend healthy lifespan. Our approach centers around developing medicines that target core aging mechanisms to treat and prevent age-related diseases. It was founded by Jim Mellon, Dr Greg Bailey and Dr Declan Doogan – with a track record of leading 2 of the 10 largest biopharma deals in the last decade, including the sale of Biohaven to Pfizer for $11.6bn. The Juvenescence team, led by Dr Richard Marshall CBE, consists of world-class R&D leadership that have previously been instrumental in the approval of medicines totalling $30bn in peak annual sales. Powered by an unrivaled drug development team, Juvenescence leverages cutting-edge AI tools to unlock successful therapeutics. The company's diverse, AI-enabled medicines pipeline of clinical and near-clinical stage candidates targeting core ageing mechanisms are in development for cognition, cardio-metabolism, immunity and cellular repair. In addition, Juvenescence has investments in a number of cutting-edge companies and platform technologies focused on AI and regenerative medicine. For more information, visit: About Ro5 In the race to save and improve lives, Ro5 accelerates drug discovery, development, repurposing, and clinical trials. We enrich our client's data with our proprietary database, then use machine learning platforms to reduce discovery time from years to months, increase accuracy, and, at every point, lower costs. Our proprietary state-of-the-art neural network architectures learn the complex relationships between a molecule's basic physicochemical properties and its more general pharmacological characteristics and are real and effective. Investor Relations Contact: juvenescenceir@ Media contact: ICR Healthcare Jessica Hodgson / Chris Welsh Juvenescence@ Forward-Looking Statements Statements in this communication relating to plans, strategies, specific activities, and other statements that are not descriptions of historical facts are forward-looking statements. Forward-looking information is inherently subject to risks and uncertainties, and actual results could differ materially from those currently anticipated due to a number of factors, which include any risks detailed from time to time in the Company's reports. Such statements are based on the management's current beliefs and expectations and are subject to significant risks and uncertainties outside of management and the Company's control. Given these uncertainties, you should not place undue reliance on these forward-looking statements, which speak only as of the date hereof. Except as otherwise required by law, the Company does not undertake any obligation, and expressly disclaims any obligation, to update, alter or otherwise revise any forward-looking statements, whether written or oral, that may be made from time to time, whether as a result of new information, future events or otherwise.
